Elsevier

Clinical Therapeutics

Volume 26, Issue 4, April 2004, Pages 493-501
Clinical Therapeutics

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis☆

https://doi.org/10.1016/S0149-2918(04)90051-3Get rights and content

Abstract

Background: Meropenem is commonly used to treat lung infections in adults with cystic fibrosis (CF). Although continuous infusion is the ideal method to maximize the pharmacodynamic properties of this betalactam antibiotic, meropenem is stable for only ∼4 to 6 hours at room temperature, and its pharmacokinetic (PK) properties, when administered by continuous infusion to patients with CF, are largely unknown.

Objective: This study was undertaken to determine the PK properties and stability of meropenem when administered to adults with CF by a continuous ambulatory drug-delivery infusion pump stored in a cold pouch between 2 freezer packs.

Methods: This open-label, multidose, randomized, crossover PK study was conducted at the Clinical Research Center at Hartford Hospital (Harford, Connecticut). Adults aged ≥ 18 years with CF were eligible. Study participants were randomized to receive meropenem 125 mg/h or 250 mg/h (equivalent to 3 g and 6 g, respectively, over 24 hours) by continuous IV infusion for 12 hours. Serum samples were collected throughout the infusion and then for 6 hours after infusion to determine the PK properties (volume of distribution [Vd], elimination rate constant, total body clearance [CL], terminal half-life [t12], and steady-state concentration [Css]). Serum meropenem concentrations were assayed using high-performance liquid chromatography, and PK profiles were determined using compartmental analysis. Meropenem stability was ascertained by sampling the drug directly from the infusion pump at prespecified time points. Meropenem tolerability was assessed throughout the study by questioning subjects on how they felt. In addition, laboratory values of serum chemistries and liver enzymes were compared with baseline values.

Results: Seven adult volunteers with CF (4 women, 3 men; mean [SD] age, 27 [10] years [range, 19–46 years]) participated in the study. Mean (SD) Css values were 8.31 (0.68) mg/L and 18.50 (3.31) mg/L for the 125-mg/h and 250-mg/h infusion rates, respectively. Vd, CL, and t12 were dose independent and similar between the 2 infusion rates. Meropenem stability was maintained over 12 and 24 hours. Meropenem by continuous infusion was well tolerated. One patient complained of a headache during the study.

Conclusions: In this study of adults with CF, meropenem infusion rates of 125 mg/h and 250 mg/h provided serum drug concentrations greater than the minimum inhibitory concentration for pathogens considered meropenem susceptible (≤ 4 μg/mL) and intermediately resistant (8 μg/mL), respectively.

References (30)

  • E.M Grant et al.

    Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

    Pharmacotherapy

    (2002)
  • J.K Thomas et al.

    Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

    Antimicrob Agents Chemother.

    (1998)
  • R.P Patel et al.

    Stability of meropenem in intravenous solutions

    Am J Health Syst Pharm.

    (1997)
  • E Viaene et al.

    Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)

    Antimicrob Agents Chemother.

    (2002)
  • S.E Walker et al.

    Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride

    Can J Hosp Pharm.

    (1998)

    • Cited by (77)

    • Critical patient's healing walks and photoprotecion: the dark side of the sun

      2023, Medicina Intensiva

    • Ceftolozane/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa

      2020, IDCases
      Citation Excerpt :

      She is colonized with methicillin-susceptible Staphylococcus aureus (MSSA) and MDR P. aeruginosa. Intravenous meropenem 2 g every 8 h infused over 3 h [16–18] and oral ciprofloxacin 500 mg twice daily were initiated empirically based on previous treatment success. However, after the second dose of meropenem the patient reported significant shortness of breath and tachycardia thought to be related to the meropenem infusion and as a result meropenem was discontinued.

    • Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis

      2018, Chest

    • The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults

      2022, Antibiotics

    • Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling

      2022, Journal of Clinical Medicine

    • Antibiotics Drive Expansion of Rare Pathogens in a Chronic Infection Microbiome Model

      2022, mSphere
    View all citing articles on Scopus
    ☆

    This study was presented in part in abstract and poster form at the 99th International Conference of the American Thoracic Society; May 16–21, 2003; Seattle, Washington.

    View full text
    Copyright © 2004 Published by Elsevier Inc.